ACH-1625, on the other hand, has a half-life of several days, which is suboptimal for an oral drug.
I don't remember any clinical information that directly leads to the conclusion that the half-life was several days. Slide 17 from the link below appears to indicate a half-life of a few hours for a 50mg/kg dose with the caveat that the dosing was done in rats
and this is part of the conclusion of a ach-1625 presentation at EASL in april
While active uptake is an apparent mechanism for liver partitioning, the data show that < 1% of the dose remains in the liver after 24 hr post dose, indicating that elimination/redistribution of the drug occurs. There was no indication of prolonged half-life in the liver compared to plasma.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.